LEUKEMIA

LEUKEMIA(英文缩写 LEUKEMIA),ISSN 0887-6924,eISSN 1476-5551 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。

指标来源：jcr_cas_ifqb

历年影响因子趋势

LEUKEMIA 最新收录文献

1. Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes.
   J-J Kiladjian, P Fenaux, A Caignard
   Leukemia 2007 IF: 8.80 Q1 PMID: 17957204
   查看详情 DOI
2. Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells.
   N Prade-Houdellier, E Frébet, C Demur, E-F Gautier, F Delhommeau, A-L Bennaceur-Griscelli
   Leukemia 2007 IF: 8.80 Q1 PMID: 17713555

   Telomerase catalytic subunit (hTERT) exerts important cellular functions including telomere homeostasis, genetic stability, cell survival and perhaps differentiation. However, the nature of external o…

   查看详情 DOI
3. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
   A Quintás-Cardama, H Kantarjian, L V Abruzzo, J Cortes
   Leukemia 2007 IF: 8.80 Q1 PMID: 17690707
   查看详情 DOI
4. Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD.
   Y Lu, J Kitaura, T Oki, Y Komeno, K Ozaki, M Kiyono
   Leukemia 2007 IF: 8.80 Q1 PMID: 17690703

   Transforming growth factor-beta (TGF-beta)-stimulated clone-22 (TSC-22) was originally isolated as a TGF-beta-inducible gene. In this study, we identified TSC-22 as a potential leukemia suppressor. Tw…

   查看详情 DOI
5. Overexpression of a hematopoietic transcriptional regulator EDAG induces myelopoiesis and suppresses lymphopoiesis in transgenic mice.
   C-Y Li, Y-Q Zhan, W Li, C-W Xu, W-X Xu, D-H Yu
   Leukemia 2007 IF: 8.80 Q1 PMID: 17690693

   Erythroid differentiation-associated gene (EDAG) is a hematopoietic tissue-specific gene that is highly expressed in the earliest CD34+ lin- bone marrow (BM) cells and involved in the proliferation an…

   查看详情 DOI
6. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells.
   T Sanda, T Okamoto, Y Uchida, H Nakagawa, S Iida, S Kayukawa
   Leukemia 2007 IF: 8.80 Q1 PMID: 17690692

   Recent reports showing successful inhibition of cancer and leukemia cell growth using histone deacetylase inhibitor (HDACi) compounds have highlighted the potential use of HDACi as anti-cancer agents.…

   查看详情 DOI
7. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group.
   D Tomizawa, K Koh, T Sato, N Kinukawa, A Morimoto, K Isoyama
   Leukemia 2007 IF: 8.80 Q1 PMID: 17690691

   We evaluated the efficacy of a treatment strategy in which infants with acute lymphoblastic leukemia (ALL) were stratified by their MLL gene status and then assigned to different risk-based therapies.…

   查看详情 DOI
8. Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia.
   D C Gilby, A C Goodeve, P R Winship, P J Valk, R Delwel, J T Reilly
   Leukemia 2007 IF: 8.80 Q1 PMID: 17657219
   查看详情 DOI
9. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
   J F Dijoseph, M M Dougher, D C Armellino, D Y Evans, N K Damle
   Leukemia 2007 IF: 8.80 Q1 PMID: 17657218

   CMC-544 (inotuzumab ozogamicin) is a CD22-specific cytotoxic immunoconjugate of calicheamicin intended for the treatment of B-lymphoid malignancies. This preclinical study investigated antitumor activ…

   查看详情 DOI
10. The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility.
    B Jahrsdorfer, S Blackwell, G Weiner
    Leukemia 2007 IF: 8.80 Q1 PMID: 17657215
    查看详情 DOI